Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Income from Continuing Operations came in at 19329000.0 in Q1 2026, down 183.83% year-on-year from 23056663.16 in Q1 2025, and down 232.06% quarter-over-quarter from 5821000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 19329000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 183.83% year-over-year to 19329000.0 in Q1 2026; TTM through Mar 2026 was 66532000.0, a 253.25% decrease from a year earlier, with the FY2025 full-year figure at 63367000.0, down 241.01% from the prior year.
- Income from Continuing Operations fell to 19329000.0 in Q1 2026 per LCTX's latest filing, from 5821000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3001000.0 in Q3 2024 and bottomed at 22535000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 6321000.0 (2022), against an average of 8216117.65.
- Across the five-year window, Income from Continuing Operations jumped 77.43% in 2022 and sank 528.02% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 6321000.0 in 2022, then rose by 25.42% to 4714000.0 in 2023, then surged by 31.06% to 3250000.0 in 2024, then slumped by 79.11% to 5821000.0 in 2025, then sank by 232.06% to 19329000.0 in 2026.
- Per Business Quant, the three latest LCTX Income from Continuing Operations figures stand at 19329000.0 (Q1 2026), 5821000.0 (Q4 2025), and 18847000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -19.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.33 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Sep 30, 2025 | -18.85 Mn |
| Jun 30, 2025 | -22.54 Mn |
| Mar 31, 2025 | -6.81 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.32 Mn |
| Sep 30, 2022 | -6.08 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.01 Mn |
| Sep 30, 2021 | -7.83 Mn |
| Jun 30, 2021 | -4.97 Mn |